Research indicates that a home-based, self-management program that promotes easy hand exercises and gives direction on moisturizing and warming effectively reduces pain and improves function in the hands of patients with systemic sclerosis.
Sarilumab shows greater efficacy relative to adalimumab or methotrexate monotherapy among rheumatoid arthritis patients with high baseline interleukin-6 levels than it does among those with low or medium levels, study findings indicate.
French researchers report a favorable COVID-19 outcome for an immunocompromised patient with spondyloarthritis treated with the tumor necrosis factor-α inhibitor etanercept.
Tapering of biologic DMARDs or Janus kinase inhibitors does not significantly reduce serious infection or serious adverse event rates in people with rheumatoid arthritis or axial spondyloarthritis, meta-analysis data show.
The authors of a prospective US case series outline the experience of 86 patients with immune-mediated inflammatory diseases and confirmed or highly suspected COVID-19.
Findings from the phase 2b CloroCovid-19 trial indicate that patients with severe suspected COVID-19 who are treated with high-dose chloroquine have higher rates of death than those given low-dose chloroquine.
High disease activity, short disease duration, and low baseline damage are associated with an increased response to belimumab in patients with systemic lupus erythematosus, real world study data show.
People with rheumatoid arthritis who visit a rheumatologist within the first 6 weeks of experiencing symptoms are more likely to achieve sustained DMARD-free remission than those who wait for 7–12 weeks, suggest observational study results.
EULAR has issued recommendations on the management of rheumatic immune-related adverse events in people with cancer treated with immune checkpoint inhibitors.
The risk for impaired left ventricular systolic function is significantly increased in patients with rheumatoid arthritis if they are positive for anticitrullinated peptide antibody, have high disease activity, and a long duration of disease, study findings suggest.
The authors of a French case series report the clinical experiences of 17 patients with systemic lupus erythematosus undergoing long-term treatment with hydroxychloroquine who developed COVID-19.
Findings from a large prospective cohort study show that regular use of a glucosamine supplement is associated with a reduced risk for all-cause and cause-specific mortality among the general population.
The US FDA has issued a safety alert warning that chloroquine and hydroxychloroquine for COVID-19 should not be used outside of hospital settings or clinical trials due to an elevated risk for heart rhythm problems with the agents.
The reported efficacy of treatments for rheumatoid arthritis is consistently higher in phase 2 than phase 3 randomized controlled trials, mainly due to differences in inclusion criteria, say the authors of a systematic review and meta-analysis.
Findings from two questionnaire studies suggest that a substantial proportion of rheumatology patients have experienced changes to their disease management since the emergence of COVID-19.
A case report published in the Annals of the Rheumatic Diseases describes the experience of a rituximab-treated patient with ANCA-associated vasculitis who developed severe COVID-19.